Alloimmune risk stratification in renal transplantation has lacked the necessary prognostic biomarkers to personalize recipient care or optimize clinical trials. HLA molecular mismatch improves precision compared to traditional antigen mismatch but has not been studied in detail at the individual molecule level. This study evaluated 664 renal transplant recipients and correlated HLA-DR/DQ single molecule eplet mismatch with serologic, histologic, and clinical outcomes. Compared to traditional HLA-DR/DQ whole antigen mismatch, HLA-DR/DQ single molecule eplet mismatch improved the correlation with de novo donor-specific antibody development (area under the curve 0.54 vs 0.84) and allowed recipients to be stratified into low, intermediate, and high alloimmune risk categories. These risk categories were significantly correlated with primary alloimmune events including Banff ≥1A T cell-mediated rejection (P = .0006), HLA-DR/DQ de novo donor-specific antibody development (P < .0001), antibody-mediated rejection (P < .0001), as well as all-cause graft loss (P = .0012) and each of these correlations persisted in multivariate models. Thus, HLA-DR/DQ single molecule eplet mismatch may represent a precise, reproducible, and widely available prognostic biomarker that can be applied to tailor immunosuppression or design clinical trials based on individual patient risk.
| INTRODUC TI ON
In a 2016 US Food and Drug Administration public meeting on patientfocused drug development, transplant recipients voiced their desire to have immunosuppressive therapy individualized and simplified to avoid side effects while ensuring efficacy. 1 Unfortunately, when induction therapy is selected for renal transplant recipients, current evidence shows that an individual's clinical risk factors only account for 10%-33% of the observed variation in practice, while transplant center effect was responsible for the majority (51%-61%) of the variation. 2 Compounding the problem, randomized controlled trials (RCTs) of immunosuppression minimization that have attempted to identify "low risk" recipients using clinical, serologic, and histologic criteria have been unsuccessful, suggesting that traditional risk factors hold little utility to personalize patient care. [3] [4] [5] Thus, an unmet need in transplantation is the accurate definition of an individual's alloimmune risk for a given donor at the time of transplant: a fundamental requirement if the field is to move to precision medicine.
In and the 2013 Transplant Society clinical practice guidelines. [6] [7] [8] The STAR 2017 report created a framework that recommended 2 independent risk assessments: 1 related to the risk of immunologic memory and a second related to the risk of a primary (ie, de novo) alloimmune response posttransplant. In this context, the STAR Working Group identified that the HLA molecular mismatch was a key determinant of an individual's primary alloimmune risk and called for research to determine optimal approaches to define HLA molecular mismatch risk categories.
In this study, building on our prior work using HLAMatchmaker as a computational tool to assess donor-recipient HLA relatedness, 9, 10 we evaluated a novel approach to quantify HLA molecu- 
| CON CIS E ME THODS

| Study population
Approval was obtained from the institutional review board (H2011:211) and was in adherence with the declaration of Helsinki.
Seven hundred twenty-four adult and pediatric consecutive renal transplants between January 1999 and July 2016 were considered for inclusion. Patients with primary nonfunction (n = 17), or pretransplant donor-specific antibody (DSA) (n = 43) were excluded, leaving 664 recipients (adult n = 606, pediatric n = 58) for analy- HLA eplet identification is based on 2 underlying principles: (a) the immune system recognizes and develops antibodies against nonselfantigens, or more specifically the epitopes on those antigens, while ignoring self-antigens/epitopes; and (b) epitope binding affinity is largely determined by a small number of polymorphic amino acids near the center of the epitope. 12 An eplet is defined as a single polymorphic amino acid or a small patch of polymorphic amino acids within a 3 angstrom (0.3 nm) radius (Figure 1) (n = 392), HLA-DRβ 5 (n = 231) donor alleles were considered. Donor null alleles at HLA-DRβ 3/4/5 (n = 224) did not count toward the total.
For HLA-DQ, α and β alleles inherited as a haplotype were considered as 1 HLA-DQ α1β1 molecule (n = 1328).
| Statistics
Comparisons between baseline predictors and clinical outcomes were done using Student t test for parametric continuous variables 
| RE SULTS
This consecutive cohort (n = 664) had a median follow-up of 91 months (range 9-13 years) after dnDSA development. Graft survival in the Class I dnDSA alone group was not different from the no dnDSA group (P = .39, Figure S1 ). Recipients who developed Class II dnDSA alone, or Class I and II dnDSA had decreased graft survival compared with those who did not develop dnDSA (P < .0001).
| Defining low risk for primary alloimmunity by HLA molecular mismatch
The Baseline demographics within these groups are compared in Table 2 .
Recipients in Group B were more likely to have a repeat transplant (P < .01), younger age (P = .03), and were less likely to have received TA B L E induction therapy (P < .01) compared to Group C. Of note, risk factors known to influence dnDSA development such as nonadherence, maintenance immunosuppression, and tacrolimus coefficient of variation were similar among the 3 groups.
| Comparison of HLA-DR/DQ mismatch quantification methods
Traditional HLA-DR/DQ whole antigen mismatch, HLA-DR/DQ eplet mismatch sum thresholds (previously published HLA-DR and DQ thresholds each ≤11), 9 and HLA-DR/DQ single molecule eplet mismatch thresholds were compared as correlates for HLA-DR/DQ dnDSA-free survival ( Figure 3 ) and Banff ≥1A TCMR-free survival ( Figure 4) . Table 1 and Figures 1 and 2 outline the key differences between these 3 methods.
Traditional HLA-DR/DQ whole antigen mismatch greater than zero was associated with significantly lower HLA-DR/DQ dnD-SA-free survival (P = .0003). However, there was no statistical difference in HLA-DR/DQ dnDSA-free survival between HLA-DR/ DQ whole antigen risk groups other than zero (P = .48, Figure 3A ).
This was also true in a locus-specific analysis of HLA-DR or HLA-DQ dnDSA development ( Figure S3 ). HLA-DR/DQ eplet mismatch sum also was associated with HLA-DR/DQ dnDSA-free survival ( Figure 3B ). Using the previously published thresholds of 11 HLA-DR or DQ eplet mismatches to risk stratify recipients, a significant doseresponse relationship was demonstrated (P < .0001, Figure 3B ). HLA-DR/DQ whole antigen mismatch greater than zero was associated with significantly decreased Banff ≥1A TCMR-free survival in the first year posttransplant (P = .0085, Figure 4A ). However, there was no difference in Banff ≥1A TCMR-free survival between HLA-DR/DQ whole antigen risk groups other than zero (P = .49, Figure 4A ). HLA-DR/DQ eplet mismatch sum was also associated with Banff ≥1A TCMR-free survival (P = .0013, Figure 4B ). However, recipients with HLA-DR ≥7 or HLA-DQ ≥9 single molecule eplet mismatches (Group C, n = 498) had significantly increased risk of Banff ≥1A TCMR (20% at 12 months, P = .0018, Figure 4C ). At least 1 renal biopsy was available in 57/72 (79%) of recipients post-dnDSA. ABMR developed in 40/57 (70%) of recipients post-dnDSA development. ABMR-free survival was significantly associated with HLA molecular mismatch risk categories (P < .0001, Figure 5C ). Correlates associated with ABMR-free survival are shown in Table S4 . Significant multivariate correlates of ABMR were recipient age (HR 0.98, 95% CI 0.96-0.99, P = .0116), nonadherence (HR 3.52, 95% CI 2.0-6.3, P < .0001), and HLA molecular mismatch risk category (HR High vs Low 5.06, 95% CI 2.1-14.9, P < .0001; HR High vs Intermediate 1.87, 95% CI 1.0-3.6, P = .0420; HR Intermediate vs Low 2.71, 95% CI 1.0-8.3, P = .0394).
| Defining intermediate and high risk for primary alloimmunity by HLA molecular mismatch
| HLA molecular mismatch correlates with allcause graft loss
Low, Intermediate, and High HLA molecular mismatch risk categories were significantly associated with all-cause graft loss (P = .0003, Figure S4 ). Correlates associated with all-cause graft loss are shown in Table S5 . In a multivariate analysis, covariates significantly associated with all-cause graft loss were recipient age (HR 1.03, 95% CI 1.01-1.04, P < .0001), delayed graft function (HR 2.56, 95% CI 1.80-3.58, P < .0001), nonadherence (HR 2.00, 95% CI 1.35-2.87, P = .0006), and alloimmune risk category (HR High vs Low 1.66, 95% CI 1.12-2.53, P = .0120; HR High vs Intermediate 1.20, 95% CI 0.9-1.7, P = .3; HR Intermediate vs Low 1.39, 95% CI 0.9-1.2, P = .1).
| D ISCUSS I ON
The key finding in this study is that in the absence of donor-specific memory (ie, no preformed DSA by solid phase single antigen bead assessment), quantifying the differences of HLA-DR/DQ mismatches at the molecular level can improve precision in primary alloimmune risk categorization. As a prognostic biomarker available pretransplant, its potential application includes the development of personalized immunosuppression protocols, as well as being a drug development tool for enrichment/stratification in clinical trial design to improve trial efficiency. These applications would address major unmet needs in transplantation from both the perspective of the patient and the pharmaceutical industry/academia. 13, 14 Traditional alloimmune risk factors reported by KDIGO and recently enumerated in the 2017 Consensus on Managing Modifiable Risk in Transplantation report were pretransplant DSA, panel reactive antibody (PRA) >0%, younger recipient age, African American ethnicity, and HLA-DR mismatch. 7, 15 Pretransplant DSA, a measure of alloimmune memory, correlates with ABMR, transplant glomerulopathy, and graft loss. 16 However, as pretransplant DSA is avoided in most kidney transplants, methods for primary alloimmune risk stratification are needed. Although elevated PRA has been correlated with allograft outcomes, recent work using state-of-the-art antibody assessment in combination with more complete HLA typing (ie, HLA-C, HLA-DQ, and HLA-DP) has shown that when preformed DSA are ruled out, calculated PRA alone is not prognostic of graft outcomes. [17] [18] [19] Younger recipient age is a well-known correlate of alloimmune risk in transplantation, likely as a result of a more robust immune system, even after adjustment for the higher prevalence of nonadherence. 10 Unfortunately, there is a lack of studies to define what age cutoff may be important, and how recipient age might be used in the precision medicine context. Although certain ethnic minorities have been associated with worse outcomes, these data are confounded by socioeconomic status, HLA mismatch, and differences in drug metabolism. 20 Moreover, population migration 
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and genetic admixture makes self-reported ethnicity increasingly imprecise such that ethnicity may be prognostic at a population level but is unlikely to have any prognostic utility at an individual level. 21, 22 Since the 1950s, HLA mismatch has been known to correlate with transplant outcome. 23 Previously, it was reported that the sum of adding the eplet mismatches within the same locus correlated with dnDSA development at that locus. 9 However, since single molecule specificity of dnDSA can be determined in most cases, the analysis can be refined further to ask if the eplet mismatch for each individual molecule correlates with the development of dnDSA to that molecule. 26 The single molecule approach would be expected to be more precise, especially for patients who have only 1 of the 2 molecules mismatched.
Using the traditional HLA whole antigen mismatch as a correlate with dnDSA development, the AUC was only 0.54 and 0.58 for HLA-DR and DQ, respectively. When applying the sum of the eplet mismatch within a locus, the AUC improved to 0.72 for both HLA-DR and DQ. 9 This was enhanced further in the current study using the The need for reliable prognostic and predictive biomarkers at the time of transplant to allow individualization of immunosuppression in patients without alloimmune memory has been recognized. 1 A prognostic biomarker is one that indicates an increased (or decreased) likelihood of a future clinical event. 27 HLA-DR/DQ molecular mismatch has consistently been shown to correlate with a significantly increased risk of dnDSA development, ABMR, transplant glomerulopathy, and graft loss after adjustment for other risk factors. [9] [10] [11] 26, 28, 29 A predictive biomarker is used to identify individuals who are more likely to respond after exposure to a particular medical product or environmental agent. 27 In this regard, Class II HLA eplet mismatch has been shown in 2 observational cohort studies and 1 RCT to identify high alloimmune risk patients who have increased rates of dnDSA development, rejection, and graft loss when immunosuppression is minimized through protocol-driven withdrawal or recipient nonadherence. 3, 9, 28 Conversely, and of equal importance, these studies also identified a subset of recipients with low alloimmune risk who tolerated immunosuppression minimization. If validated in prospective clinical trials, this would provide the evidence that HLA-DR/DQ single molecule mismatch can act as both a prognostic and a predictive biomarker capable of identifying which individuals require more or less immunosuppression to control their primary alloimmune response. 21 As a prognostic biomarker, HLA-DR/DQ molecular mismatch has several favorable characteristics. It is available at the time of transplant, modern HLA typing methods already provide the inputs necessary for its evaluation, and analysis software is free and is already being incorporated into HLA typing software from vendors. Thus, HLA-DR/DQ molecular mismatch is cost effective, reproducible, and will be widely available in histocompatibility laboratories.
At present, given excellent short-term clinical outcomes, the evaluation of novel drugs focuses on the average treatment effect in the overall kidney transplant population requiring Phase 3 clinical trials lasting ≥5 years with relatively large sample sizes to demonstrate superiority to standard of care. [13] [14] [15] 30 This inefficient trial design is in part due to the lack of robust and precise pretransplant risk assessment for primarily alloimmune events resulting in the inclusion of heterogeneous populations. Using the HLA-DR/DQ molecular mismatch score as a prognostic biomarker could significantly address this issue by enriching Phase 2 and 3 clinical trials with patients based upon risk categorization in studies evaluating novel drugs.
| Limitations
Due to the relatively small sample size and the associated risk of type II error, risk quantification should be interpreted with caution, and should be validated in an independent cohort. Histology was available in 79% of recipients in the first year posttransplant; however, 97% of the death-censored graft loss occurred in the cohort with at least 1 biopsy. Methods of risk stratification will need to be tested prospectively and in independent cohorts with varying ethnicities to confirm their general applicability.
| CON CLUS IONS
A prerequisite to precision medicine is a prognostic biomarker that correlates with clinical outcomes, is reproducible, and ideally is widely available and cost effective. Using thresholds identified for dnDSA development as an outcome, we show that the HLA-DR/DQ molecular mismatch score allows for low-, intermediate-, and highrisk stratification for Banff ≥1A TCMR, dnDSA development, ABMR, and all-cause graft loss. Given that all transplant programs worldwide are supported by accredited histocompatibility laboratories, this biomarker could be readily applied at little additional cost. Once validated, the HLA-DR/DQ molecular mismatch score could be used to tailor immunosuppression based on individual patient risk, as well as in the design of clinical trials.
